The genetic landscape of diffuse large B-cell lymphoma

Semin Hematol. 2015 Apr;52(2):67-76. doi: 10.1053/j.seminhematol.2015.01.005. Epub 2015 Jan 17.


Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in the western world, is an aggressive disease that remains incurable in approximately 30% of patients. Over the past decade, the rapid expansion of sequencing technologies allowing the genome-wide assessment of genomic and transcriptional changes has revolutionized our understanding of the genetic basis of DLBCL by providing a comprehensive and unbiased view of the genes/pathways that are disrupted by genetic alterations in this disease, and may contribute to tumor initiation and expansion. These studies uncovered the existence of several previously unappreciated alterations in key cellular pathways that may also influence treatment outcome. Indeed, a number of newly identified genetic lesions are currently being explored as markers for improved diagnosis and risk stratification, or are entering clinical trials as promising therapeutic targets. This review focuses on recent advances in the genomic characterization of DLBCL and discusses how information gained from these efforts has provided new insights into its biology, uncovering potential targets of prognostic and therapeutic relevance.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • B-Lymphocytes / immunology
  • B-Lymphocytes / pathology
  • Cell Differentiation
  • Genomics
  • Humans
  • Lymphocyte Activation
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Mutation